Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jun 18;11(6):841.
doi: 10.3390/cancers11060841.

Current Treatment Landscape for Advanced Hepatocellular Carcinoma: Patient Outcomes and the Impact on Quality of Life

Daneng Li  1 , Sabrina Sedano  2 , Rebecca Allen  3 , Jun Gong  4 , May Cho  5 , Sunil Sharma  6
Affiliations
Review

Current Treatment Landscape for Advanced Hepatocellular Carcinoma: Patient Outcomes and the Impact on Quality of Life

Daneng Li et al. Cancers (Basel). .

Abstract

Hepatocellular carcinoma (HCC) is the fifth most common cancer and the second leading cause of cancer mortality worldwide. Heterogeneity of clinical conditions contributes to the complex management of care for patients with advanced HCC. Recently, the treatment landscape for advanced HCC has expanded rapidly, with the additional FDA approvals of several oral tyrosine kinase inhibitors (lenvatinib, regorafenib, and cabozantinib), as well as immunotherapies such as immune check point inhibitors (nivolumab and pembrolizumab) and the monoclonal IgG1 antibody, ramucirumab. This expansion has generated a need for novel treatment sequencing strategies in this patient population. In light of these developments, an evaluation of the impact of FDA-approved therapeutics on patient-centered outcomes such as health-related quality of life (HRQoL) is warranted. An increased understanding of HRQoL in patients included in advanced HCC clinical trials could potentially help physician decision-making for treatment sequencing in patients with advanced HCC.

Keywords: hepatocellular carcinoma; quality of life; systemic therapy.

PubMed Disclaimer

Conflict of interest statement

D.L. receives research funding from Brooklyn ImmunoTherapeutics. He serves as a consultant and has honoraria from Lexicon, Novartis, Ipsen, Advanced Accelerator Applications, Exelixis, and Bayer. J.G. serves as a consultant and has honoraria from Amgen, and Astellas. M.C. serves as a consultant and has honoraria from Amgen, Taiho, Astella, Ipsen and Exelixis. Sunil Sharma (S.S.) receives clinical research funding from Novartis, GSK, Millennium, MedImmune, Johnson & Johnson, Gilead Sciences, Plexxikon, Onyx, Bayer, Blueprint Medicines, XuanZhu, Incyte, Toray Industries, Celgene, Hengrui Therapeutics, OncoMed, Tesaro, AADi, and Syndax. He holds equity from Salarius Pharmaceuticals, Iterion Therapeutics, Proterus Therapeutics, ConverGene, and Stingray Therapeutics and owns stock in LSK BioPharma. Sunil Sharma (S.S.) also has honoraria from Exelixis, Loxo Oncology, Hengrui Therapeutics, Tarveda Therapeutics, and Dracen Pharmaceuticals. Other authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The current treatment landscape for advanced HCC.
See this image and copyright information in PMC

References

    1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. McGlynn K.A., London W.T. The Global Epidemiology of Hepatocellular Carcinoma, Present and Future. Clin. Liver Dis. 2011;15:223–234. doi: 10.1016/j.cld.2011.03.006. - DOI - PMC - PubMed
    1. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–2576. doi: 10.1053/j.gastro.2007.04.061. - DOI - PubMed
    1. Llovet J.M., Zucman-Rossi J., Pikarsky E., Sangro B., Schwartz M., Sherman M., Gores G. Hepatocellular carcinoma. Nat. Rev. Dis. Primers. 2016;2:16018. doi: 10.1038/nrdp.2016.18. - DOI - PubMed
    1. Mittal S., El-Serag H.B. Epidemiology of HCC: Consider the Population. J. Clin. Gastroenterol. 2013;47:S2–S6. doi: 10.1097/MCG.0b013e3182872f29. - DOI - PMC - PubMed

LinkOut - more resources